These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 37502434)

  • 21. Emerging concepts in the detection of liver fibrosis in non-alcoholic fatty liver disease.
    Armandi A; Michel M; Gjini K; Emrich T; Bugianesi E; Schattenberg JM
    Expert Rev Mol Diagn; 2023; 23(9):771-782. PubMed ID: 37505901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Galectin-12 modulates Kupffer cell polarization to alter the progression of nonalcoholic fatty liver disease.
    Lee JL; Wang YC; Hsu YA; Chen CS; Weng RC; Lu YP; Chuang CY; Wan L
    Glycobiology; 2023 Oct; 33(8):673-682. PubMed ID: 37504513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of decompensated cirrhosis in children: A population-based study.
    Kehar M; Griffiths R; Flemming JA
    Can Liver J; 2023 Jul; 6(2):278-282. PubMed ID: 37503518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel predictors of early atherosclerosis in nonalcoholic fatty liver disease.
    Abdulaziz BA; Bendary AM; Thabet A; Behery EG; Salah M; Khalil MA; Rashad G
    Clin Exp Hepatol; 2023 Jun; 9(2):106-114. PubMed ID: 37502438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hypercholesterolemia and cardiovascular risk].
    Sinning D; Landmesser U
    Dtsch Med Wochenschr; 2023 Aug; 148(16):1025-1032. PubMed ID: 37541292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significant roles of potential genes and their mutations in nonalcoholic fatty liver disease.
    Sokouti B
    Clin Exp Hepatol; 2023 Jun; 9(2):95-105. PubMed ID: 37502439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Pemafibrate on the Lipid Profile, Liver Function, and Liver Fibrosis Among Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Hassan M; Al-Obaidi H; Karrick M; Merza N; Nawras Y; Saab O; Al-Obaidi AD; Merza F; Hashim HT; Al Zubaidi K; Al-Sabbagh D; Matbachi R; Noori Z; Amatul-Raheem H; Mansur S; Al Najafi O; Algodi M; Al Hamdany T; Kobeissy A
    Gastroenterology Res; 2024 Aug; 17(4):159-174. PubMed ID: 39247710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel Selective PPARĪ± Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis.
    Yamashita S; Rizzo M; Su TC; Masuda D
    Metabolites; 2023 May; 13(5):. PubMed ID: 37233667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of body composition and liver function after long-term pemafibrate treatment on dyslipidemia-associated non-alcoholic fatty liver disease.
    Ishikawa T; Terai N; Igarashi T; Yamazaki S; Kobayashi T; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
    Clin Exp Hepatol; 2023 Jun; 9(2):172-178. PubMed ID: 37502434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease.
    Shinozaki S; Tahara T; Lefor AK; Ogura M
    Clin Exp Hepatol; 2020 Sep; 6(3):270-274. PubMed ID: 33145434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study.
    Shinozaki S; Tahara T; Miura K; Lefor AK; Yamamoto H
    Life (Basel); 2023 Jun; 13(6):. PubMed ID: 37374110
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan-aspartate aminotransferase score.
    Hatanaka T; Kosone T; Saito N; Takakusagi S; Tojima H; Naganuma A; Takagi H; Uraoka T; Kakizaki S
    JGH Open; 2021 Oct; 5(10):1183-1189. PubMed ID: 34622006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study.
    Shinozaki S; Tahara T; Lefor AK; Ogura M
    Clin Exp Hepatol; 2021 Jun; 7(2):172-177. PubMed ID: 34295984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gamma-glutamyl transferase predicts pemafibrate treatment response in non-alcoholic fatty liver disease.
    Takahashi Y; Seko Y; Yamaguchi K; Takeuchi K; Yano K; Kataoka S; Moriguchi M; Itoh Y
    J Gastroenterol Hepatol; 2023 Oct; 38(10):1743-1749. PubMed ID: 37221601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The potential function and clinical application of FGF21 in metabolic diseases.
    Chen Z; Yang L; Liu Y; Huang P; Song H; Zheng P
    Front Pharmacol; 2022; 13():1089214. PubMed ID: 36618930
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.